Efficacy and Safety of 500mg of Fulvestrant

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-04-30

Study Completion Date

2026-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fulvestrant has proven effective in the treatment of hormone receptor positive metastatic breast cancer. The dose used in studies so far has been well tolerated and may be too low for optimal effectiveness. In this study, a higher dose will be used to see whether an improved outcome will result.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer

NCT00146601

Breast Cancer

COMPLETED PHASE2

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

NCT00099437

Breast Cancer

ACTIVE_NOT_RECRUITING PHASE3

Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer

NCT00871858

Breast Cancer

COMPLETED PHASE2

A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer

NCT00274469

Metastatic Breast Cancer

COMPLETED PHASE2

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

NCT01602380

Hormone Receptor Positive Breast Cancer

ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Fulvestrant will be administered by intramuscular injection on day 1, day 15 and day 29 and then every 28 days thereafter.
* Participants will have a physical examination and blood work performed on each treatment date. After teh study treatment has been completed, the physical examinations will be done every three months for the first 2 years, every 6 months for years 2-5, and annually after 5 years.
* Participants may remain on study treatment until disease progression or until they experience serious side effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

single

fulvestrant 500mg

Group Type EXPERIMENTAL

Fulvestrant

Intervention Type DRUG

500mg into the muscle on days 1, 15 and 29 and then every 28 days thereafter.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fulvestrant

500mg into the muscle on days 1, 15 and 29 and then every 28 days thereafter.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Faslodex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female
* 18 years of age or older
* Histologically confirmed adenocarcinoma of the breast progressing local-regional or metastatic disease that is not considered amenable to curative treatment
* Evidence of hormone sensitivity of primary or secondary tumor tissue
* Postmenopausal as defined by criteria listed in protocol
* May have had adjuvant endocrine therapy if discontinued at least 12 months prior to inclusion. Subjects who have had minimal exposure to adjuvant or first line metastatic endocrine treatment during the 12 months prior to study enrollment can be eligible with overall PI and sponsor permission
* Prior trastuzumab and biologic therapy is allowed, but must be discontinued more than 2 weeks prior to inclusion
* Presence of measurable or evaluable, nonmeasurable, disease. Any x-rays and scans for assessment of measurable disease must be performed with 28 days prior to registration
* Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2

Exclusion Criteria

* Presence of life-threatening metastatic disease
* Endocrine therapy the advanced disease setting
* Systemic chemotherapy, whether as adjuvant therapy or for advanced disease, within previous 4 weeks
* Trastuzumab or biologic therapy within previous 2 weeks
* Extensive radiation therapy within the last 2 weeks
* Prior adjuvant or neoadjuvant treatment with fulvestrant is not allowed
* Concomitant anticancer treatments
* Chronic bisphosphonates for hypercalcemia or prevention of bone metastases
* Subjects receiving long-term anticoagulant therapy with warfarin
* Estrogen replacement therapy within 6 months of trial entry
* Previous or current systems malignancy within the past 3 years
* Treatment with non approved or investigational drug within 2 weeks before study entry
* Any evidence of severe or uncontrolled systemic disease
* History of bleeding diathesis
* Any severe concomitant condition which makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the study protocol

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No